跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MINT-GLICLAZIDE MR - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
MINT-GLICLAZIDE MR
Authorized
STANDARD
MINT-GLICLAZIDE MR
mint pharmaceuticals inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
e237e16f0e4403ad
Company
mint pharmaceuticals inc
Type
Standard
Approval Details
Approval Id
e237e16f0e4403ad
Drug Approval Canada Name
MINT-GLICLAZIDE MR
Product Name
MINT-GLICLAZIDE MR
Status
Marketed
Status Date
2025-04-16
Original Market Date
2016-11-14
Din
02423294
Drug Class
Human
Dosage Form
Tablet (Extended-Release)
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:20.20
Atc Original
A10BB09 GLICLAZIDE
Atc Name
a 10 bb 09
Aig Number
0119934003
Company Name
mint pharmaceuticals inc
Company Address
6575 Davand Drive, Mississauga, Ontario, Canada, L5T 2M3
Active Ingredients
GLICLAZIDE
60 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
e237e16f0e4403ad
Type
Standard
Back to Health Canada Approvals